BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//SVACS - ECPv6.15.1.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SVACS
X-ORIGINAL-URL:https://www.siliconvalleyacs.org
X-WR-CALDESC:Events for SVACS
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260603T090000
DTEND;TZID=America/Los_Angeles:20260603T103000
DTSTAMP:20260618T162843
CREATED:20260508T210303Z
LAST-MODIFIED:20260508T210523Z
UID:22740-1780477200-1780482600@www.siliconvalleyacs.org
SUMMARY:Emerging Medicinal Chemistry Approaches to Targeting Disease Pathways
DESCRIPTION:Sponsored by ACS Publications\nJune 3\, 9:00-10:30 am\, Online\, Free\, Registration required \nThis session spotlights cutting edge medicinal chemistry strategies that are reshaping how we understand and target complex disease pathways. Featuring winners of the 2026 Philip S. Portoghese Early Career Award for the Advancement of Medicinal Chemistry\, it will shine light on the dark kinome and explore how proximity inducing chemical approaches are unlocking new ways to modulate protein function and open the door to transformative therapeutic possibilities.
URL:https://www.siliconvalleyacs.org/event/emerging-medicinal-chemistry-approaches-to-targeting-disease-pathways/
LOCATION:Virtual
CATEGORIES:Webinar
ATTACH;FMTTYPE=image/jpeg:https://www.siliconvalleyacs.org/wp-content/uploads/2026/05/Emerging-MedChem-Approaches-to-Targeting-Disease-Pathways-e1778274117697.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20260608T170000
DTEND;TZID=America/Los_Angeles:20260608T190000
DTSTAMP:20260618T162843
CREATED:20260514T185859Z
LAST-MODIFIED:20260602T191937Z
UID:22751-1780938000-1780945200@www.siliconvalleyacs.org
SUMMARY:Reprogramming How We Interface with the Human Body:                           High-Resolution 3D Printing Can Make the Unmakeable
DESCRIPTION:Prof. Joseph M. DeSimone\, Departments of Radiology and Chemical Engineering\, Stanford University\nThe seminar on Monday\, June 8\, starts at 6:00 PM Pacific time.\nAn in-person networking hour on the Stanford campus precedes the live presentation from 5:00 – 6:00 PM.\nRegistration required for campus location or for Zoom link.  Registration deadline: Sunday\, June 7\, 1:00 PM. \n\nAbstract\nThroughout my career\, I’ve been guided by the belief that transformative advances in medicine don’t arise solely from new molecules\, but equally from rethinking how those molecules are formulated and delivered to the body. This mindset has led to a series of unconventional dosage and delivery innovations—from biodegradable drug-eluting stents (BVS\, Inc.\, acquired by Guidant and now part of Abbott; co-founded with Bob Langer)\, to precisely engineered microparticles for inhalation (Liquidia Technologies; NASDAQ: LQDA)\, to iontophoretic platforms for localized chemotherapy (Focal Medical; IND approved by the FDA\, with patients treated beginning March 2026)—each opening new therapeutic frontiers. \nToday\, advances in high-resolution 3D printing are enabling a new chapter in this journey: the ability to engineer the skin as a programmable biological interface. Using microscale additive manufacturing\, we can create intradermal delivery systems that precisely control where and how therapeutics are introduced\, while simultaneously enabling access to rich biological information through interstitial fluid. \nThis bi-directional paradigm—delivering therapies while sampling biology—opens a fundamentally new approach to medicine. By targeting the skin and its underlying lymphatic network\, we can more effectively engage the immune system\, access early disease signals\, and move beyond traditional blood-based diagnostics toward continuous\, minimally invasive liquid biopsy. \nImportantly\, this is not simply a new device or formulation—it represents a scalable platform. Rather than building a traditional therapeutic pipeline molecule by molecule\, these technologies enable a delivery-centric model that can be applied broadly across vaccines\, biologics\, and diagnostics. \nIn this talk\, I will outline how focusing on new dosage delivery forms and new devices for liquid biopsies—now powered by high-resolution 3D printing—is redefining our interface with the human body\, transforming both how we treat disease and how we measure health. \nSpeaker Background\nJoseph M. DeSimone \nSanjiv Sam Gambhir Professor of Translational Medicine and Chemical Engineering \nDepartments of Radiology and Chemical Engineering \nDepartment of Chemistry (by Courtesy) \nDepartment of Materials Science & Engineering (by Courtesy) \nGraduate School of Business (by Courtesy) \nStanford University \nProf. DeSimone is widely known by the Bay Area polymer science community and the academic world\, and his background\, interests\, and accomplishments are extensive and wide-ranging\, and far too long to fit in this note. For further information\, please see Stanford links: \nStanford Profile: https://profiles.stanford.edu/joseph-desimone \nResearch Group Website: https://desimonegroup.stanford.edu
URL:https://www.siliconvalleyacs.org/event/reprogramming-how-we-interface-with-the-human-body-how-high-resolution-3d-printing-can-make-the-unmakeable/
LOCATION:Hybrid
CATEGORIES:Webinar,Lecture
ATTACH;FMTTYPE=application/pdf:https://www.siliconvalleyacs.org/wp-content/uploads/2026/05/DeSimone_8June26_JointGGPF-SVACS_FLYER.pdf
END:VEVENT
END:VCALENDAR